Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegavivint With or Without Decitabine in Relapsed/Refractory AML
NCT04874480Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2021
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tegavivint in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events up to 2 years, Response rate up to 2 years and 3 more. Started Sep 2021; status: active, not recruiting.
02
Drugs
tegavivint
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04874480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04874480.